<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36896834</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of medicine</Title><ISOAbbreviation>Ann Med</ISOAbbreviation></Journal><ArticleTitle>Significance of co-positivity for anti-dsDNA, -nucleosome, and -histone antibodies in patients with lupus nephritis.</ArticleTitle><Pagination><StartPage>1009</StartPage><EndPage>1017</EndPage><MedlinePgn>1009-1017</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2023.2187076</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The aim of this study was to define the clinical, histopathologic, and prognostic features associated with simultaneous positivity for anti-dsDNA, -nucleosome, and -histone antibodies (3-pos) in Korean patients with biopsy-proven lupus nephritis (LN).</AbstractText><AbstractText Label="METHODS">The 102 patients included in the study had undergone kidney biopsy prior to the start of induction treatment, were treated with immunosuppressives, and followed-up for &gt;12&#x2009;months.</AbstractText><AbstractText Label="RESULTS">In total, 44 (43.1%) of the 102 LN patients were 3-pos. Patients with 3-pos had a higher SLEDAI-2K score (<i>p</i>&#x2009;=&#x2009;.002), lower lymphocyte count (<i>p</i>&#x2009;=&#x2009;.004), and higher rates of proteinuria &gt; 3.5&#x2009;g/24&#x2009;h (<i>p</i>&#x2009;=&#x2009;.039) and positivity for urinary sediments (<i>p</i>&#x2009;=&#x2009;.005) at the time of renal biopsy than non-3-pos patients. 3-pos patients had a more proliferative form of LN (<i>p</i>&#x2009;=&#x2009;.045) in the renal histopathologic findings, and as co-positivity gradually increased from 0 to 3, the total activity score in the renal biopsy findings increased significantly (<i>p</i>&#x2009;=&#x2009;.033). In addition, 3-pos patients had a more rapid eGFR decline than non-3-pos patients after a follow-up of 83.2&#x2009;months (<i>p</i>&#x2009;=&#x2009;.016).</AbstractText><AbstractText Label="CONCLUSIONS">Our findings suggest that 3-pos is related to severe LN and that 3-pos patients are more likely to experience a rapid decline of renal function than non-3-pos patients.KEY MESSAGEPatients with co-positivity for anti-dsDNA, -nucleosome, and -histone antibodies (3-pos) had higher disease activity and a worse renal histopathology than those without co-positivity.3-pos patients had a more rapid decline of renal function than non-3-pos patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sung-Eun</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School &amp; Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Dong-Jin</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School &amp; Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Ji-Hyoun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School &amp; Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Shin-Seok</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0001-6810-7355</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School &amp; Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med</MedlineTA><NlmUniqueID>8906388</NlmUniqueID><ISSNLinking>0785-3890</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009707">Nucleosomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009707" MajorTopicYN="Y">Nucleosomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lupus nephritis</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">pathology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36896834</ArticleId><ArticleId IdType="doi">10.1080/07853890.2023.2187076</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>